- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV-VEC vector system (AAV-VEC expression system, AAV-VEC packaging plasmid system ) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi (GM) AAV-VEC Vector system is including: 1) AAV-VEC Rep-Cap plasmid (AAV-VEC-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).
You can produce AAV-VEC particle in 293T cell line in high titer using GeneMedi's AAV-VEC Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV-VEC vector has been validated in endothelium, with potential applications in tissue-specific gene therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.
Go to AAV
vector system
>>
Map Download
Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | First Order Discount | First Order Discount Price |
|---|---|---|---|---|---|
| P-PK26 | AAV-VEC Vector System (Amp resistance) 1. AAV-VEC Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 3379 | 50% | 1689.5 |
| P-PK26 | AAV-VEC Vector System (Amp resistance) 1. AAV-VEC Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Biotech & Pharma & Medical Device & Diagnostics | 50% | ||
| P-PK26 | AAV-VEC Vector System (Amp resistance) 1. AAV-VEC Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
50% | ||
| P-PK26 | AAV-VEC Vector System (Amp resistance) 1. AAV-VEC Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK26-Kan | AAV-VEC Vector System (Kan resistance) 1. AAV-VEC Rep-Cap Plasmid (Kan resistance) , ≥10mg 2. AAV Helper Plasmid (Kan resistance) , ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-RC26 | AAV-VEC Rep-Cap
Plasmid (Amp resistance)
Size：5ug |
Academic | 2062 | 50% | 1031 |
| P-RC26 | AAV-VEC Rep-Cap
Plasmid (Amp resistance)
Size：5ug | Biotech & Pharma & Medical Device & Diagnostics | 50% | ||
| P-RC26 | AAV-VEC Rep-Cap
Plasmid (Amp resistance)
Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
50% | ||
| P-RC26 | AAV-VEC Rep-Cap
Plasmid (Amp resistance)
Size：≥10mg |
All | |||
| P-RC26-Kan | AAV-VEC Rep-Cap
Plasmid(Kan resistance)
Size：≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity | Signal Transduction and Targeted Therapy | 2022/6/24 |
| Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p | Journal of Extracellular Vesicles | 2021/1/18 |
| SUPPLEMENTARY MATERIALS AND METHODS | Ann Rheum Dis | |
| Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma | nature communications | 2022/7/21 |
| The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis | Nature Communications | 2019/7/2 |
| VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf2/HO-1 Signaling Pathway in Diabetic Nephropathy | Advanced Science | 2023/12/25 |
| Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator | Acta Pharmaceutica Sinica B | 2022/7/21 |
| Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2 | nature metabolism | 2021/11/8 |
| ABRO1 arrests postnatal cardiomyocyte proliferation and myocardial repair by blocking N6-methyladenosine methylation and expression of PSPH | Molecular Therapy | 2023/1/13 |
| The Involvement of PGRMC1Signaling in Cognitive Impairment Induced by Long-Term Clozapine Treatment in Rats | Neuropsychobiology | 2023/9/6 |
Validation data
No data found
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
